Full Text Journal Articles by
Author Paul Cornes

Advertisement

Find full text journal articles








Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.

Paul Cornes, Pere Gascon, Arnold G Vulto, Matti Aapro,

Febrile neutropenia (FN) is a serious complication of chemotherapy, which can cause significant morbidity and mortality, result in dose delays and reductions and, ultimately, reduce cancer survival. Over the past decade, the availability of biosimilar filgrastim (short-acting granulocyte colony-stimulating factor [G-CSF]) has transformed patient access, with clear evidence of clinical ... Read more >>

BioDrugs (BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy)
[2020, 34(3):255-263]

Cited: 1 time

View full text PDF listing >>



The evolution of value with filgrastim in oncology.

Paul Cornes, Andriy Krendyukov,

The recombinant G-CSF filgrastim was first approved in 1991, and its value has been evolving ever since. Initial health technology assessments suggested low value due to high drug cost and no evidence for significant gain in overall survival. However, more recent meta-analyses of placebo-controlled randomized trial data show falling costs ... Read more >>

Future Oncol (Future oncology (London, England))
[2019, 15(13):1525-1533]

Cited: 0 times

View full text PDF listing >>



Advertisement

Correction to: Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.

Paul Cornes, Pere Gascon, Stephen Chan, Khalid Hameed, Catherine R Mitchell, Polly Field, Mark Latymer, Luiz H Arantes,

The article "Systematic Review and Meta-analysis of Short-versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia", written by Paul Cornes, Pere Gascon, Stephen Chan, Khalid Hameed, Catherine R. Mitchell, Polly Field, Mark Latymer, Luiz H. Arantes Jr was originally published electronically on the publisher's internet portal (currently SpringerLink) ... Read more >>

Adv Ther (Advances in therapy)
[2018, 35(11):1830]

Cited: 0 times

View full text PDF listing >>



Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile Neutropenia.

Paul Cornes, Pere Gascon, Stephen Chan, Khalid Hameed, Catherine R Mitchell, Polly Field, Mark Latymer, Luiz H Arantes,

<h4>Introduction</h4>Short- and long-acting granulocyte-colony stimulating factors (G-CSFs) are approved for the reduction of febrile neutropenia. A systematic literature review was performed to identify randomized controlled trials (RCTs) and non-RCTs reporting the use of G-CSFs following chemotherapy treatment.<h4>Methods</h4>Medline<sup>®</sup>/Medline in-process, Embase<sup>®</sup>, and the Cochrane Library were searched for studies published between January ... Read more >>

Adv Ther (Advances in therapy)
[2018, 35(11):1816-1829]

Cited: 3 times

View full text PDF listing >>



The changing landscape of biosimilars in rheumatology.

Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay, Tore K Kvien, Josef Smolen, Yoshiya Tanaka, Gerd R Burmester,

Biosimilars remain a hot topic in rheumatology, and some physicians are cautious about their application in the real world. With many products coming to market and a wealth of guidelines and recommendations concerning their use, there is a need to understand the changing landscape and the real clinical and health-economic ... Read more >>

Ann Rheum Dis (Annals of the rheumatic diseases)
[2016, 75(6):974-982]

Cited: 74 times

View full text PDF listing >>



Chemotherapy for metastatic and recurrent cervical cancer.

Kate Scatchard, Jennifer L Forrest, Maxine Flubacher, Paul Cornes, Chris Williams,

<h4>Background</h4>Cervical cancer is the second most common cancer among women up to 65 years of age and is the most frequent cause of death from gynaecological cancers worldwide. A woman's risk of developing cervical cancer by 65 years of age ranges from 0.69% in developed countries to 1.38% in developing ... Read more >>

Cochrane Database Syst Rev (The Cochrane database of systematic reviews)
[2012, 10:CD006469]

Cited: 23 times

View full text PDF listing >>



Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer.

Matti Aapro, Paul Cornes, Diana Sun, Ivo Abraham,

<h4>Objectives</h4>To evaluate the comparative cost efficiency across the European Union G5 countries of the erythropoiesis-stimulating agents (ESAs) epoetin α (originator [Eprex®] and biosimilar [Binocrit®]; once weekly), epoetin β (NeoRecormon®; once weekly), and darbepoetin α (Aranesp®; once weekly or once every 3 weeks) under different scenarios of fixed and weight-based dosing ... Read more >>

Ther Adv Med Oncol (Therapeutic advances in medical oncology)
[2012, 4(3):95-105]

Cited: 24 times

View full text PDF listing >>



The economic pressures for biosimilar drug use in cancer medicine.

Paul Cornes,

The main rationale for using biosimilar drugs is for cost saving. The market development for biosimilar drugs will therefore depend on the degree to which cost saving measures are required by nations, medical insurers and individuals and the absolute savings that could be gained by switching from original drugs. This ... Read more >>

Target Oncol (Targeted oncology)
[2012, 7 Suppl 1:S57-67]

Cited: 36 times

View full text PDF listing >>



Adjuvant chemotherapy for endometrial cancer after hysterectomy.

Nick Johnson, Andrew Bryant, Tracie Miles, Thomas Hogberg, Paul Cornes,

<h4>Background</h4>Endometrial adenocarcinoma (womb cancer) is a malignant growth of the lining (endometrium) of the womb (uterus). It is distinct from sarcomas (tumours of the uterine muscle). Survival depends the risk of microscopic metastases after surgery. Adjuvant (postoperative) chemotherapy improves survival from some other adenocarcinomas, and there is evidence that endometrial ... Read more >>

Cochrane Database Syst Rev (The Cochrane database of systematic reviews)
[2011, (10):CD003175]

Cited: 24 times

View full text PDF listing >>



Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.

Matti Aapro, Paul Cornes, Ivo Abraham,

<h4>Objectives</h4>This cost-efficiency analysis of the granulocyte colony-stimulating factors (G-CSF) filgrastim (originator Neupogen® and biosimilar Zarzio®) and pegfilgrastim (Neulasta®) examined against a time horizon of 1-14 days of treatment and across the European Union G5 countries (a) when, cost-wise, using Neulasta® 6 mg versus Neupogen® or Zarzio® 300 µg may be ... Read more >>

J Oncol Pharm Pract (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners)
[2012, 18(2):171-179]

Cited: 44 times

View full text PDF listing >>



Health state utility scores for cancer-related anemia through societal and patient valuations.

Andrew Lloyd, Patricia van Hanswijck de Jonge, Scott Doyle, Paul Cornes,

<h4>Objectives</h4>Fatigue is recognized as the most serious complication of chemotherapy for the majority of patients. This study aims to determine preferences and utility values for health state descriptions of anemia associated with cancer treatment.<h4>Methods</h4>FACT-An clinical trial data were summarized to define health states associated with hemoglobin levels of 7.0-8.0, 8.0-9.0, ... Read more >>

Value Health (Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research)
[2008, 11(7):1178-1185]

Cited: 18 times

View full text PDF listing >>



Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

Martin Reck, Hans-Nikol Macha, Sonia Del Barco, Paul Cornes, Nathalie Vaissière, Maryse Morand, Marcello Riggi, Raymond Abratt,

<h4>Introduction</h4>This phase II study assessed the efficacy and safety of oral vinorelbine given weekly in combination with carboplatin (CBDCA) AUC 5 once every 3 weeks for four cycles in chemonaive patients with advanced non-small cell lung carcinoma (NSCLC), followed by consolidation therapy with single-agent oral vinorelbine in non-progressive patients.<h4>Methods</h4>Chemonaive advanced ... Read more >>

Lung Cancer (Lung cancer (Amsterdam, Netherlands))
[2009, 64(3):319-325]

Cited: 7 times

View full text PDF listing >>



Brachytherapy in endometrial cancer: quantification of air gaps around a vaginal cylinder.

Alison L Cameron, Paul Cornes, Hoda Al-Booz,

PURPOSE: Vaginal vault brachytherapy, prescribed to 0.5 cm, is used in endometrial cancer postoperatively to reduce the risk of vault recurrence. However, it is unknown if the vaginal mucosa is closely opposed to the vaginal cylinder, or if air gaps lift the mucosa from the cylinder. The aim of this ... Read more >>

Brachytherapy (Brachytherapy)
[2008, 7(4):355-358]

Cited: 14 times

View full text PDF listing >>



Erythropoietins should be used according to guidelines.

Matti S Aapro, Gunnar Birgegård, Carsten Bokemeyer, Paul Cornes, Jan Foubert, Pere Gascon, John Glaspy, Eva Hellström-Lindberg, Hartmut Link, Heinz Ludwig, Anders Osterborg, Lazzaro Repetto, Pierre Soubeyran,

Lancet Oncol (The Lancet. Oncology)
[2008, 9(5):412-413]

Cited: 16 times

View full text PDF listing >>



Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.

Anders Osterborg, Matti Aapro, Paul Cornes, Anton Haselbeck, Colin R W Hayward, Wolfgang Jelkmann,

In vitro and animal model studies have shown erythropoietin receptor (Epo-R) mRNA and/or protein may be present in a range of human tumours and cancer cell lines, and erythropoiesis-stimulating agents (ESAs) have been reported to have tumour cell growth-modulating effects. Following a review of the literature, we conclude that considerations ... Read more >>

Eur J Cancer (European journal of cancer (Oxford, England : 1990))
[2007, 43(3):510-519]

Cited: 41 times

View full text PDF listing >>



Sigmoid colon is an unexpected organ at risk in brachytherapy for cervix cancer.

Hoda Al-Booz, Ion Boiangiu, Helen Appleby, Chris French, Helen Coomber, Pauline Humphery, Paul Cornes,

PURPOSE:To identify organs at risk (OAR) and analyze the dose volume histograms (DVHs) for intracavitary brachytherapy in cancer of the cervix. Late toxicities are our concern in treatment of cancer cervix especially as it is presenting in younger age population. MATERIAL AND METHODS:Patients with cancer of the cervix were treated ... Read more >>

J Egypt Natl Canc Inst (Journal of the Egyptian National Cancer Institute)
[2006, 18(2):156-160]

Cited: 7 times

View full text PDF listing >>



Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.

Paul Cornes, Bertrand Coiffier, Jean-Jacques Zambrowski,

<h4>Background</h4>Healthcare organizations must evaluate the cost effectiveness of the alternative therapies that are available to treat anemia and improve quality of life (QoL) of patients with cancer, that is, erythropoietic protein therapy and blood transfusion.<h4>Methods</h4>Pharmacoeconomic studies that evaluated the cost of not treating anemia or treating with transfusion or erythropoietic ... Read more >>

Curr Med Res Opin (Current medical research and opinion)
[2007, 23(2):357-368]

Cited: 9 times

View full text PDF listing >>



Brachytherapy vs. IMRT for irradiation of the vaginal vault: in regard to Aydogan et al. (Int J Radiat Oncol Biol Phys 2006;65:266-273).

Alison Cameron, Paul Cornes,

Int J Radiat Oncol Biol Phys (International journal of radiation oncology, biology, physics)
[2006, 66(3):956; author reply 956-7]

Cited: 0 times

View full text PDF listing >>



Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy.

Lone Gothard, Paul Cornes, Sonja Brooker, Judith Earl, John Glees, Emma Hall, Clare Peckitt, Diana Tait, John Yarnold,

<h4>Background and purpose</h4>Radiation-induced tissue fibrosis is a common adverse effect of curative treatment for pelvic cancer. Pilot studies testing alpha-tocopherol and pentoxifylline provide evidence of clinical regression of superficial radiation fibrosis after radiotherapy.<h4>Patients and methods</h4>Twenty-seven eligible research volunteers with a minimum of one grade 3 or 4 disability (LENT SOMA) ... Read more >>

Radiother Oncol (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology)
[2005, 75(3):334-341]

Cited: 19 times

View full text PDF listing >>



Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.

Lone Gothard, Paul Cornes, Judith Earl, Emma Hall, Julie MacLaren, Peter Mortimer, John Peacock, Clare Peckitt, Mary Woods, John Yarnold,

<h4>Background and purpose</h4>Treatment-induced arm lymphoedema is a common and distressing complication of curative surgery and radiotherapy for early breast cancer. A number of studies testing alpha-tocopherol (vitamin E) and pentoxifylline suggest evidence of clinical regression of superficial radiation-induced fibrosis but there is only very limited evidence from randomised trials. Arm ... Read more >>

Radiother Oncol (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology)
[2004, 73(2):133-139]

Cited: 42 times

View full text PDF listing >>



Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy.

Raj Ragoowansi, Paul G S Cornes, Anthony L Moss, John P Glees,

The authors report the outcomes of patients with keloid scars treated with a protocol of extralesional excision and immediate single-fraction adjuvant radiotherapy. The design of the study was a retrospective analysis with up to 5-year outcome data. The setting was a single treatment team, University Teaching Hospital in London, United ... Read more >>

Plast Reconstr Surg (Plastic and reconstructive surgery)
[2003, 111(6):1853-1859]

Cited: 81 times

View full text PDF listing >>



Radiotherapy for rectal cancer.

Paul G S Cornes, Mehdi Shahidi,

N Engl J Med (The New England journal of medicine)
[2002, 346(2):137-138]

Cited: 2 times

View full text PDF listing >>



Intraoperative Irradiation: Techniques and Results

Paul Cornes,

J R Soc Med (Journal of the Royal Society of Medicine)
[1999, 92(8):434-434]

Cited: 0 times

View full text PDF listing >>





Advertisement

Disclaimer
1.0354 s